ICA 2023 | Dalian, China

Introduction of ICA-2023

The Annual International Congress of Antibodies (ICA), initiated from 2009, had been successfully organized in Beijing, Hangzhou Dalian and Nanjing, attracted more than 3,500 participants from 60 countries. ICA series congresses contribute to offering professionals in the field of antibody a multidisciplinary informative cooperative platform, and it has been the most definite and grand Antibody event in Asia. The ICA-2023 will be held during April 25-29, 2023 at Dalian World Expo Center, China.

Programmed Chapters at a Glance

Opening Ceremony and Keynote Forum
ICA 01: Antibody Market and Trends
ICA 02: Future Landscape of Therapeutic Antibody Discovery Technology
ICA 03: Antibody Structure in Relation to Function
ICA 04: High-Throughput Antibody Discovery and Engineering
ICA 05: Antibody Library Design, Selection and Screening
ICA 06: Most Charming Targets for Therapeutic Antibody Designs
ICA 07: Antibody-ADCs and Multi-Specific Antibodies as Next Big Things
ICA 08: Antibodies as Diagnostic Biomarkers
ICA 09: Alternative Applications of Versatile Antibodies
ICA 10: Facinating MABs from Non-Human Primates
ICA 11: Smart Antibody DDS
ICA 12: Antibody Clinical Trials
ICA 13: Antibody Engineering and Bioanalysis
ICA 14: Biosimilars and Biosuperiors of Antibody Therapy
ICA 15: Antibody Repertoires and COVID-19
ICA 16: Next Wave of Immuno-oncology Therapeutic Antibodies
ICA 17: Antibodies for Autoimmune Disease
ICA 18: Antibodies Against Infectious Disease Agents
ICA 19: Next Generation Genetically Engineered Antibody
ICA 20: Antibody Custom Services

Renowned Speakers of Previous Events

Dr. Bruce A. Beutler, Professor, UT Southwestern, USA Nobel Prize laureate in Physiology or Medicine, 2011	Dr. Tim Hunt, Emeritus Group Leader, Clare Hall Laboratories, UK Nobel Prize laureate in Physiology or Medicine, 2001	Dr. Steven J. Swanson, Senior Vice President, ImmunoCellular Therapeutics, Ltd., USA
Dr. Mitchell Ho, Senior Investigator, National Cancer Institute, NIH, USA	Dr. Thomas J. Webster, Art Zafirpoulo Chair, Chair Department of Chemical Engineering, Northeastern University, USA	Ms. Robin Barbour, Head, Prothena Corporation, USA
Dr. Jing Li, Senior Vice President, WuXi Biologics, China	Dr. William R. Alley, Jr., Senior Scientist, Waters Corp., USA	Dr. Eric Risser, Senior Vice President, MacroGenics, Inc., USA
Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc., Canada	Dr. Weikang Tao, Vice President and CEO of R&D Center, Jiangsu Henrui Medicine Co., Ltd., China	Dr. Esther Una Cidon, Professor, Royal Bournemouth Hospital, UK
Ms. Ningling Wang, Managing Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, China	Dr. Z. Ying Li, Partner, Steptoe & Johnson LLP, USA	Dr. Weiping Shao, Director, Regeneron Pharmaceuticals, Inc., USA
Dr. Lidia Anna Retkowska-Mika, Director, Office for Registration of Medicinal Products, Medical Devices and Biocides, Poland	Dr. Ulrich Storz, Senior Partner, Michalski•Hüttermann & Partner, Germany	Dr. George Lovrecz, Adjunct Professor, RMIT University, Australia
Ms. Xingmei Tan, Senior Engineer, Abcam(Hangzhou)Biotechnology Co. Ltd., China	Dr. Mark I. Fitchmun, President and Senior Advisor, Somatek. Inc., USA	Dr. Nirmesh Shah, Director, Apobiologix, USA
Dr. Matthew F. Heil, Chief Scientific Officer, Curemark LLC, USA	Dr. Carole Schante, Principal Scientist, Novartis, Switzerland	Dr. Marcus Mreyen, Director, Protagen Protein Services GmbH, Germany
Dr. Candida Fratazzi, President, BBCR Consulting, USA	Dr. Shawn Guse, President and CEO, Intuitive Biosciences, USA	Dr. Abhishek Saharia, Director, DiscoveRx Corporation, USA
Dr. David Franco, Head, GSK Vaccines, Belgium	Dr. Hui Zhao, Principal Scientist, Agensys, USA	Dr. Xianbin Yang, Director of R & D, AM Biotechnologies, USA
Dr. Steve Xiaofeng Yu, Director, Cyagen Biosciences, Inc, China	Dr. Patrick Liu, Vice President, Teva Pharmaceuticals Ltd., USA	Dr. Martin Welschof, CEO, Opsona Therapeutics Ltd, Ireland
Dr. Matthias Germer, Senior Director, Biotest AG, Germany	Dr. William L. Klein, Professor, University of California - Los Angeles, USA	Dr. Kevin Heyries, Co-Founder, AbCellera, Canada

Exhibition and Poster

ICA-2023 provides an ideal platform to showcase your novel technologies and products. It is developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent repeated opportunities for delegates to visit the exhibits.
Why Reserve a Booth at ICA-2023
• To Meet Face-to-Face with the International Movers and Shakers
• To Meet with Key Decision Marker
• To Explore Business Opportunities
• To Spotlight Advanced Technologies and Their Scientific and Commercial Applications
• To Take Advantage of the Conference's Captive Audience and Networking Opportunities within the Exhibition Hall

Introduction of Dalian

Dalian — the "Northern Pearl" and summer resort of China, compared to ancient capital cities such as Beijing, Xian, Nanjing or Xi’an, is a young city with only a 100-year history. Dalian is the most relaxed and livable city in Northeast China. In many parts of China, economic prosperity comes at the price of clean air and charm. Not so in Dalian, whose natural blessings are its biggest asset. Tree-lined, hilly streets, dotted colonial architectures, an impressive coastline with beaches, as well as its prosperous town, have made it being dubbed as the "Hong Kong of the North China". It is one of the three Best Tourism Cities (2006), along with Hangzhou and Chengdu, recognized by the National Tourism Administration.

Online Registration

Earlybird Registration Now

News Released